Corbus Pharmaceuticals (CRBP) Expected to Announce Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($1.02) per share for the quarter.

Corbus Pharmaceuticals Price Performance

Shares of NASDAQ CRBP traded down $0.18 during mid-day trading on Friday, reaching $6.79. The company's stock had a trading volume of 168,155 shares, compared to its average volume of 247,677. The stock has a fifty day moving average of $10.09 and a two-hundred day moving average of $21.18. The firm has a market capitalization of $82.70 million, a PE ratio of -1.45 and a beta of 2.63. Corbus Pharmaceuticals has a 52 week low of $6.54 and a 52 week high of $61.90.

Analyst Upgrades and Downgrades

CRBP has been the subject of a number of research analyst reports. StockNews.com upgraded Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday. HC Wainwright restated a "buy" rating and set a $75.00 price target on shares of Corbus Pharmaceuticals in a report on Tuesday, February 18th. William Blair initiated coverage on Corbus Pharmaceuticals in a research note on Friday, February 28th. They issued an "outperform" rating on the stock. Finally, Piper Sandler initiated coverage on Corbus Pharmaceuticals in a research report on Monday, December 2nd. They set an "overweight" rating and a $35.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $63.57.

Remove Ads

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.